Bictegravir is a second-generation HIV-1 integrase strand transfer inhibitor (INSTI). It inhibits HIV-1 integrase, an enzyme required for integration of viral DNA into the host-cell genome. Bictegravir is used as an active pharmaceutical ingredient in antiretroviral formulations, including combination therapy for HIV-1 infection.
Bictegravir is commonly formulated as its sodium salt, Bictegravir Sodium, in pharmaceutical products. The sodium salt has a molecular weight of 471.4 g/mol and CAS 1807988-02-8.
PubChem confirms the molecular formula, molecular weight and CAS number of Bictegravir, as well as its use as an HIV-1 integrase inhibitor.
Bictegravir is used as an API for:
Bictegravir inhibits HIV-1 integrase strand transfer activity, preventing integration of viral DNA into the host-cell genome. This interferes with the HIV replication cycle.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | Conforms by validated chromatographic / spectroscopic method |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |